MatchMedi
한국어

Options mapped

Huntington's disease: options by country

Sourced options by country plus visit-prep questions for Huntington's disease. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedRare diseaseLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

  • Is chorea the symptom being targeted, or are mood, cognition, sleep, swallowing, or behavior the priority?
  • Are depression or suicidality risks being actively assessed before VMAT2 inhibitor use?
  • Is the planned VMAT2 inhibitor covered by the local formulary or insurance plan?
  • Are chorea, psychiatric symptoms, or swallowing/falls driving the treatment decision?

Trial-search terms to discuss

Huntington's disease clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

  • Tetrabenazine / Xenazine; deutetrabenazine / Austedo and Austedo XR; valbenazine / Ingrezza and Ingrezza Sprinkle[1]FDA-approvedHuntington disease clinical/genetic diagnosis; CAG expansion confirmation appears in some trial criteria, but VMAT2 labels are symptom/diagnosis framed; Symptomatic treatment of chorea associated with Huntington's disease in adults for deutetrabenazine/valbenazine; chorea associated with Huntington's disease for tetrabenazine. · VMAT2 inhibitor labels include depression/suicidality warnings in Huntington's disease. These medicines address chorea symptoms and do not treat all cognitive, psychiatric, or functional features of Huntington's disease. Confidence/conflicts: High for U.S. label-supported symptomatic chorea options; no disease-modifying claim is made.
  • Tetrabenazine / Xenazine; deutetrabenazine / Austedo and Austedo XR; valbenazine / Ingrezza and Ingrezza Sprinkle[1]FDA-approvedHuntington disease clinical/genetic diagnosis; CAG expansion confirmation appears in some trial criteria, but VMAT2 labels are symptom/diagnosis framed; Symptomatic treatment of chorea associated with Huntington's disease in adults for deutetrabenazine/valbenazine; chorea associated with Huntington's disease for tetrabenazine. · VMAT2 inhibitor labels include depression/suicidality warnings in Huntington's disease. These medicines address chorea symptoms and do not treat all cognitive, psychiatric, or functional features of Huntington's disease. Confidence/conflicts: High for U.S. label-supported symptomatic chorea options; no disease-modifying claim is made.

European Union

  • Tetrabenazine; second-generation neuroleptics/antipsychotics; supportive multidisciplinary care[2]Standard option (per European Medicines Agency)Huntington disease diagnosis; no specific biomarker required for symptomatic chorea guidelines; Symptomatic chorea and behavioral/psychiatric symptom contexts in Huntington's disease. · Guideline article is not a national regulator or reimbursement document. EMA Austedo page fetched this cycle did not support a Huntington indication. UK tetrabenazine source is referenced in a PMDA review report and needs direct MHRA/UK label verification. Confidence/conflicts: Medium-high. Guideline support is verified, but EU/UK national approval and reimbursement require direct labels before patient-facing integration.

Australia

  • chorea-directed drug treatment; physiotherapy; assistive equipment and mobility aids; speech and language therapy; psychological support; palliative care[3]Standard option (per Rare Awareness Rare Education Portal / Rare Voices Australia)HTT CAG-repeat expansion; Australian multidisciplinary supportive-care context throughout HD progression. · The RARE Portal is educational, not a drug label, reimbursement rule, or individualized care plan. It does not identify which chorea medicine is approved or funded. Confidence/conflicts: High for Australian supportive-care framing; no conflict identified.
  • deutetrabenazine (Austedo)[4]ApprovedHTT CAG-repeat expansion context; chorea associated with Huntington's disease; symptomatic treatment of chorea associated with Huntington's disease. · Austedo is symptomatic; it does not establish a disease-modifying or curative treatment. The product-information attachment states it may have been superseded and current TGA PI should be checked. Confidence/conflicts: High for Australian deutetrabenazine indication in fetched PI attachment; current PI/PBS implementation remains source-pending. Availability/reimbursement outside the approving regulator not established.
  • deutetrabenazine (Austedo)[4]ApprovedHTT CAG-repeat expansion context; chorea associated with Huntington's disease; symptomatic treatment of chorea associated with Huntington's disease. · Austedo is symptomatic; it does not establish a disease-modifying or curative treatment. The product-information attachment states it may have been superseded and current TGA PI should be checked. Confidence/conflicts: High for Australian deutetrabenazine indication in fetched PI attachment; current PI/PBS implementation remains source-pending. Availability/reimbursement outside the approving regulator not established.

Canada

  • long-term care supports; outpatient HD clinic/primary care; physical, cognitive, psychiatric, and therapy services[5]Standard option (per Canadian Institute for Health Information)HTT CAG-repeat expansion context; Canadian routine clinic, long-term care, and supportive-service context for adult HD. · CIHI is a health-system analysis, not a prescribing label or individual care guideline. It documents care patterns and gaps but does not define eligibility for specific services. Confidence/conflicts: High for Canadian health-system/supportive-care context; no conflict identified.
  • tetrabenazine (Tetrabenazine Tablets; Nitoman class context)[6]ApprovedHuntington's chorea / hyperkinetic movement disorder context; symptomatic treatment of chorea/hyperkinetic movements associated with Huntington disease in Canada. · The product monograph includes major depression/suicidality warnings and contraindications, including active suicidality, untreated or inadequately treated depression, hepatic impairment, MAOI use, and reserpine use. It does not claim disease modification. Confidence/conflicts: Medium-high; tetrabenazine is verified in Canadian monograph context and CIHI national analysis, while brand-specific current DPD details remain a follow-up. Availability/reimbursement outside the approving regulator not established.
  • tetrabenazine (Tetrabenazine Tablets; Nitoman class context)[6]ApprovedHuntington's chorea / hyperkinetic movement disorder context; symptomatic treatment of chorea/hyperkinetic movements associated with Huntington disease in Canada. · The product monograph includes major depression/suicidality warnings and contraindications, including active suicidality, untreated or inadequately treated depression, hepatic impairment, MAOI use, and reserpine use. It does not claim disease modification. Confidence/conflicts: Medium-high; tetrabenazine is verified in Canadian monograph context and CIHI national analysis, while brand-specific current DPD details remain a follow-up. Availability/reimbursement outside the approving regulator not established.

Sources

  1. DailyMed / U.S. National Library of Medicine — official drug-label index · official drug-label index
  2. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  3. Rare Awareness Rare Education (RARE) Portal / Rare Voices Australia — Australian rare-disease educational portal · Australian rare-disease educational portal
  4. Therapeutic Goods Administration (TGA) / Teva Pharma Australia — AusPAR product-information attachment · AusPAR product-information attachment
  5. Canadian Institute for Health Information (CIHI) — national health system analysis · national health system analysis
  6. Health Canada / SteriMax product monograph repository — official product monograph · official product monograph

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • AMT-130 intra-striatal rAAV5-miHTT; RO7234292/RG6042 intrathecal therapy; WVE-120101Clinical trial · NCT04120493Clinical trialTrial only (registry)United States · HTT CAG expansion at least 40 repeats for AMT-130; targeted SNP1 rs362307 for WVE-120101 extension; manifest Huntington disease criteria for RO7234292 extension; Early manifest Huntington's disease for AMT-130; prior Roche/Genentech study participants for RO7234292 extension; prior WVE-HDSNP1-001 completers with targeted SNP1 context for WVE-120101 extension. · WVE-120101 record is terminated; RO7234292 record is completed; AMT-130 is active-not-recruiting in the fetched record. Trial-specific neurosurgical/intrathecal risks and eligibility are not generalized. Confidence/conflicts: High for registry status and geography; no approval claim is made. ClinicalTrials.gov — clinical-trial registry
  • AMT-130 intra-striatal rAAV5-miHTT; RO7234292/RG6042 intrathecal therapy; WVE-120101Clinical trial · NCT04120493Clinical trialTrial only (registry)United States · HTT CAG expansion at least 40 repeats for AMT-130; targeted SNP1 rs362307 for WVE-120101 extension; manifest Huntington disease criteria for RO7234292 extension; Early manifest Huntington's disease for AMT-130; prior Roche/Genentech study participants for RO7234292 extension; prior WVE-HDSNP1-001 completers with targeted SNP1 context for WVE-120101 extension. · WVE-120101 record is terminated; RO7234292 record is completed; AMT-130 is active-not-recruiting in the fetched record. Trial-specific neurosurgical/intrathecal risks and eligibility are not generalized. Confidence/conflicts: High for registry status and geography; no approval claim is made. ClinicalTrials.gov — clinical-trial registry
  • AMT-130 intra-striatal rAAV5-miHTT; RO7234292/RG6042 intrathecal therapy; WVE-120101Clinical trial · NCT04120493Clinical trialTrial only (registry)United States · HTT CAG expansion at least 40 repeats for AMT-130; targeted SNP1 rs362307 for WVE-120101 extension; manifest Huntington disease criteria for RO7234292 extension; Early manifest Huntington's disease for AMT-130; prior Roche/Genentech study participants for RO7234292 extension; prior WVE-HDSNP1-001 completers with targeted SNP1 context for WVE-120101 extension. · WVE-120101 record is terminated; RO7234292 record is completed; AMT-130 is active-not-recruiting in the fetched record. Trial-specific neurosurgical/intrathecal risks and eligibility are not generalized. Confidence/conflicts: High for registry status and geography; no approval claim is made. ClinicalTrials.gov — clinical-trial registry
  • SD-809/deutetrabenazine extended release; transcranial direct-current stimulation (tDCS); sham comparatorClinical trial · NCT01897896Clinical trialTrial only (registry)United States · Manifest Huntington disease with expanded CAG repeat in deutetrabenazine trial; confirmed HD mutation and/or family history plus symptoms in tDCS trial; Chorea associated with Huntington disease for SD-809/deutetrabenazine extension/switch trial; cognitive and behavioral symptoms for tDCS pilot feasibility study. · tDCS is trial-framed and not recorded as routine treatment. ARC-HD is completed and supports registry evidence, not current enrollment. Confidence/conflicts: High for trial records; no routine tDCS availability claim is made. ClinicalTrials.gov — clinical-trial registry
  • SD-809/deutetrabenazine extended release; transcranial direct-current stimulation (tDCS); sham comparatorClinical trial · NCT01897896Clinical trialTrial only (registry)United States · Manifest Huntington disease with expanded CAG repeat in deutetrabenazine trial; confirmed HD mutation and/or family history plus symptoms in tDCS trial; Chorea associated with Huntington disease for SD-809/deutetrabenazine extension/switch trial; cognitive and behavioral symptoms for tDCS pilot feasibility study. · tDCS is trial-framed and not recorded as routine treatment. ARC-HD is completed and supports registry evidence, not current enrollment. Confidence/conflicts: High for trial records; no routine tDCS availability claim is made. ClinicalTrials.gov — clinical-trial registry
  • pridopidineClinical trialClinical trialInvestigationalCanada · clinical HD with at least 36 CAG repeats in the huntingtin gene per trial inclusion; adults aged 25 years and older with adult-onset stage 1 or 2 HD in a clinical-trial context. · Trial listing does not establish approval, efficacy, disease modification, or individual eligibility. The source points to ClinicalTrials.gov for most recent updates. Confidence/conflicts: Medium-high for Canadian trial listing; current ClinicalTrials.gov status should be rechecked before patient-facing reuse. Huntington Society of Canada — clinical-trial listing / patient organization trial page
  • pridopidineClinical trialClinical trialInvestigationalCanada · clinical HD with at least 36 CAG repeats in the huntingtin gene per trial inclusion; adults aged 25 years and older with adult-onset stage 1 or 2 HD in a clinical-trial context. · Trial listing does not establish approval, efficacy, disease modification, or individual eligibility. The source points to ClinicalTrials.gov for most recent updates. Confidence/conflicts: Medium-high for Canadian trial listing; current ClinicalTrials.gov status should be rechecked before patient-facing reuse. Huntington Society of Canada — clinical-trial listing / patient organization trial page

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.